Radar > 234062

Biolab plans US entry

Biolab vai entrar nos Estados Unidos

Intel ID : 234062
Synopsis

Biolab, a drug manufacturer based in São Paulo, will enter the United States market, as published by newspaper Estadão on 21 February 2016, citing Drummond's lawyer and partner, Pedro Drummond.

According to the news, the company opened an office in Miami to look for business, and hired Drummond consulting firm as an adviser for this operation, the United States entry.
(content in portuguese)

A Biolab, fabricante de medicamentos com sede em São Paulo, vai entrar nos Estados Unidos, segundo publicou o Estadaõ em 21 de fevereiro de 2016, citando ao advogado e sócio da empresa Drummond, Pedro Drummond.

De acordo com a notícia, a empresa já abriu um escritório em Miami para prospecção de negócios e contratou a consultora Drummond como assessora para a operação de entrar no mercado norte-americano.

Bidder

Biolab
Brazil

Advisors

retained

Intel ID 234062
Value ND
Native Currency Brazilian Real (BRL)
Exchange Rate:
Financial Data - Biolab
(31 Dec 2018)
Revenue: EUR 262,14m
EBITDA: EUR 47,18m
Exchange Rate:
Date
Country
Region
Continent
Geography
Subsector (Old TTR Sectors)
Type
Intel Grade
Source
Tags

Bidder

Name
verified
Subsector (Old TTR Sectors)
Industry / Pharmaceutical, Parapharmaceutical and Cosmetics (Primary)
Primary Sector (TTRSC)
30.01.03 Pharmaceutical R&D, Manufacturing & Distribution
30 Healthcare / 30.01 Biotechnology & Pharmaceuticals

Secondary Sectors (TTRSC)
30.01.01 Biopharmaceuticals
30 Healthcare / 30.01 Biotechnology & Pharmaceuticals

30.01.04 Specialty Pharmaceuticals
30 Healthcare / 30.01 Biotechnology & Pharmaceuticals

Country
Website
Description

Other

Legend:

verified Verified: Confirmed as a party to an active or possible transaction.

potential Potential: Unconfirmed as a party to an active or possible transaction.

retained Retained: Confirmed as “Retained” with a general or specific mandate.

prospect Prospect: Advisory “Prospect” in discussions with or pitching services to possible client.

Transactional data is continuously updated by the research team and therefore is subject to change.